Mardirosoff C, Dumont L
Department of Anesthesiology, Université Libre de Bruxelles, Belgium.
Anesth Analg. 1999 Nov;89(5):1263-6.
In this study, we evaluated the effect of two doses of intrathecal sufentanil combined with bupivacaine and epinephrine on the incidence of pruritus and on the duration and quality of analgesia. One hundred five parturients were enrolled in this randomized, double-blinded, placebo-controlled study. They received either intrathecal 1.25 mg bupivacaine and 25 microg epinephrine (control group); 1.25 mg bupivacaine, 25 microg epinephrine, and 2.5 microg sufentanil (2.5-microg group); or 1.25 mg bupivacaine, 25 microg epinephrine, and 5 microg (5-microg group). Pain relief was assessed 10 min after injection, and pruritus was recorded at 30 min by a blinded observer. The study ended when the parturients requested further analgesia. There were no demographic differences among groups. Ninety of 103 parturients achieved complete pain relief with the initial dose, 11 patients in the control group (P < 0.004, control versus both sufentanil groups), and 2 patients in the 2.5-microg group needed a supplemental epidural bupivacaine. Pruritus was absent in the control group (P < 0.0001, control versus both sufentanil groups), whereas it was present in 36% of the 2.5-microg group and in 66% of the 5-microg group (P = 0.015, 2.5-microg versus 5-microg group). The mean duration of analgesia was similar in patients receiving sufentanil (2.5-microg group: 133 +/- 55 min; 5-microg group: 142 +/- 52 min) but was significantly higher than the control group (56 +/- 32 min). Reducing the sufentanil dose from 5 microg to 2.5 microg when combined with bupivacaine and epinephrine, decreases the incidence of pruritus without impeding the quality or duration of analgesia.
We evaluated two different doses of intrathecal sufentanil combined with bupivacaine and epinephrine for labor analgesia. Sufentanil 2.5 microg offered an advantage over sufentanil 5 microg because, while providing the same quality and duration of analgesia, it was associated with a reduced incidence of pruritus.
在本研究中,我们评估了两种剂量的鞘内注射舒芬太尼联合布比卡因和肾上腺素对瘙痒发生率以及镇痛持续时间和质量的影响。105名产妇参与了这项随机、双盲、安慰剂对照研究。她们分别接受鞘内注射1.25mg布比卡因和25μg肾上腺素(对照组);1.25mg布比卡因、25μg肾上腺素和2.5μg舒芬太尼(2.5μg组);或1.25mg布比卡因、25μg肾上腺素和5μg舒芬太尼(5μg组)。注射后10分钟评估疼痛缓解情况,30分钟时由一名盲法观察者记录瘙痒情况。当产妇要求进一步镇痛时,研究结束。各组之间在人口统计学方面无差异。103名产妇中有90名在初始剂量时实现了完全疼痛缓解,对照组中有11名患者(P<0.004,对照组与两个舒芬太尼组相比),2.5μg组中有2名患者需要补充硬膜外布比卡因。对照组未出现瘙痒(P<0.0001,对照组与两个舒芬太尼组相比),而2.5μg组中有36%的患者出现瘙痒,5μg组中有66%的患者出现瘙痒(P=0.015,2.5μg组与5μg组相比)。接受舒芬太尼的患者的平均镇痛持续时间相似(2.5μg组:133±55分钟;5μg组:142±52分钟),但显著长于对照组(56±32分钟)。当与布比卡因和肾上腺素联合使用时,将舒芬太尼剂量从5μg降至2.5μg,可降低瘙痒发生率,且不影响镇痛质量或持续时间。
我们评估了两种不同剂量的鞘内注射舒芬太尼联合布比卡因和肾上腺素用于分娩镇痛。2.5μg舒芬太尼比5μg舒芬太尼具有优势,因为在提供相同质量和持续时间的镇痛效果时,其瘙痒发生率较低。